IL317679A - Methods for treating previously untreated follicular lymphoma with mosunatuzumab and nalididomide - Google Patents

Methods for treating previously untreated follicular lymphoma with mosunatuzumab and nalididomide

Info

Publication number
IL317679A
IL317679A IL317679A IL31767924A IL317679A IL 317679 A IL317679 A IL 317679A IL 317679 A IL317679 A IL 317679A IL 31767924 A IL31767924 A IL 31767924A IL 317679 A IL317679 A IL 317679A
Authority
IL
Israel
Prior art keywords
dose
mosunetuzumab
administered
dosing cycle
rasburicase
Prior art date
Application number
IL317679A
Other languages
English (en)
Hebrew (he)
Original Assignee
Genentech Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Hoffmann La Roche filed Critical Genentech Inc
Publication of IL317679A publication Critical patent/IL317679A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL317679A 2022-06-22 2023-06-21 Methods for treating previously untreated follicular lymphoma with mosunatuzumab and nalididomide IL317679A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263354491P 2022-06-22 2022-06-22
PCT/US2023/068804 WO2023250367A1 (en) 2022-06-22 2023-06-21 Methods for treatment of previously untreated follicular lymphoma with mosunetuzumab and lenalidomide

Publications (1)

Publication Number Publication Date
IL317679A true IL317679A (en) 2025-02-01

Family

ID=87519897

Family Applications (1)

Application Number Title Priority Date Filing Date
IL317679A IL317679A (en) 2022-06-22 2023-06-21 Methods for treating previously untreated follicular lymphoma with mosunatuzumab and nalididomide

Country Status (11)

Country Link
US (1) US20240043553A1 (cg-RX-API-DMAC7.html)
EP (1) EP4543546A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025521501A (cg-RX-API-DMAC7.html)
KR (1) KR20250025678A (cg-RX-API-DMAC7.html)
CN (1) CN119546334A (cg-RX-API-DMAC7.html)
AU (1) AU2023286618A1 (cg-RX-API-DMAC7.html)
CA (1) CA3259327A1 (cg-RX-API-DMAC7.html)
IL (1) IL317679A (cg-RX-API-DMAC7.html)
MX (1) MX2024015750A (cg-RX-API-DMAC7.html)
TW (1) TWI881370B (cg-RX-API-DMAC7.html)
WO (1) WO2023250367A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026006456A1 (en) * 2024-06-25 2026-01-02 Genentech, Inc. Methods of treating cancer using subcutaneous dosing of mosunetuzumab as a monotherapy or in combination with lenalidomide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
IL301086A (en) * 2020-09-10 2023-05-01 Genmab As Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
WO2022098638A2 (en) * 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
JP7716473B2 (ja) * 2020-11-04 2025-07-31 ジェネンテック, インコーポレイテッド 抗cd20/抗cd3二重特異性抗体の皮下投薬
WO2026006456A1 (en) * 2024-06-25 2026-01-02 Genentech, Inc. Methods of treating cancer using subcutaneous dosing of mosunetuzumab as a monotherapy or in combination with lenalidomide

Also Published As

Publication number Publication date
JP2025521501A (ja) 2025-07-10
TWI881370B (zh) 2025-04-21
CA3259327A1 (en) 2023-12-28
MX2024015750A (es) 2025-02-10
WO2023250367A1 (en) 2023-12-28
CN119546334A (zh) 2025-02-28
KR20250025678A (ko) 2025-02-24
EP4543546A1 (en) 2025-04-30
TW202409075A (zh) 2024-03-01
US20240043553A1 (en) 2024-02-08
AU2023286618A1 (en) 2025-01-09

Similar Documents

Publication Publication Date Title
Büchner et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.
Gottlieb et al. Chemotherapy of malignant lymphoma with adriamycin
Rowinsky Update on the antitumor activity of paclitaxel in clinical trials
JP2022549621A5 (cg-RX-API-DMAC7.html)
Ferrara et al. Vincristine as salvage treatment for refractory thrombotic thrombocytopenic purpura
JPS62145029A (ja) インタ−フエロン組成物
Frakes et al. An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant
JP2025521501A5 (cg-RX-API-DMAC7.html)
WO1995024927A1 (en) Immunotherapeutic method of treating cancerous diseases by administration of gamma globulins
Gottlieb et al. Whether or not to Administer Amphotericin to an Immunosuppressed Patient with Hematologic Malignancy and Undiagnosed Fevert
US5756514A (en) Methods for treatment and prevention of drug-induced pruritus with serotonin type 3 receptor antagonists
Adamczyk et al. A 12-year old girl with severe plaque psoriasis and Down syndrome treated successfuly with etanercept
Cersosimo et al. Acute hypotensive reaction to etoposide with successful rechallenge: case report and review of the literature
Suzuki et al. Primary plasma cell leukemia: a case report of successful responder to a combination chemotherapy of vincristine, doxorubicin and dexamethasone
RU2024139114A (ru) Способы лечения ранее нелеченной фолликулярной лимфомы с помощью мосунетузумаба и леналидомида
Petrova et al. Efficacy and safety of SGLT2 inhibitors in patients with type 2 diabetes mellitus: a systematic review
Sanborn et al. Efficacy of dacarbazine (DTIC) in preventing metastases arising from intraocular melanomas in mice
Avanzini et al. INSIGHT and NORDIL
Gorschlüter et al. Successful induction and consolidation therapy of acute myeloid leukaemia in a renal allograft recipient.
US5571800A (en) Method for inhibiting allograft rejection by the administration of 6-azauridine or its triacetate derivative
Roila et al. Antiemetic activity of two different high doses and schedules of metoclopramide in dacarbazine-treated cancer patients
Sleight Surival following thrombolytic therapy
JPH0251405B2 (cg-RX-API-DMAC7.html)
Bazzoli et al. Efficacy of omeprazole plus amoxicillin or amoxicillin plus clarithromyicin for 1 week or 2 weeks for Hericobacter pylori eradication in patients with duodenal ulcer
Doyle Long-Term Data Support Use of Acalabrutinib in Treatment-Naïve Patients with Chronic Lymphocytic Leukemia.